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Abstract: Formaldehyde (FA) fixation of infectious samples is a well-established protocol 
in diagnostic electron microscopy of viruses. However, published experimental data that 
demonstrate virus inactivation by these fixation procedures are lacking. Usually, fixation is 
performed immediately before the sample preparation for microscopy. The fixation 
procedure should transform viruses in a non–infectious but nonetheless structurally intact 
form in order to allow a proper diagnosis based on morphology. FA provides an essential 
advantage in comparison to other disinfectants, because it preserves the ultrastructure of 
biological material without interfering significantly with the preparation (i.e., the negative 
staining) and the detection of viruses. To examine the efficiency of FA inactivation, we  
used Vaccinia virus, Human adenovirus and Murine norovirus as models and treated  
them with FA under various conditions. Critical parameters for the inactivation efficiency 
were the temperature, the duration of the FA treatment, and the resistance of the virus in 
question. Our results show that FA inactivation at low temperature (4 °C) bears a high  
risk of incomplete inactivation. Higher temperatures (25 °C) are more efficient, although 
they still require rather long incubation times to fully inactivate a complex and highly  
robust virus like Vaccinia. A protocol, which applied 2% buffered FA for 60 min and a  
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temperature–shift from 25 to 37 °C after 30 min was efficient for the complete inactivation 
of all test viruses, and therefore has the potential to improve both biosafety and speed of 
diagnostic electron microscopy. 
Keywords: formaldehyde; inactivation; plaque assay; TCID50 assay; diagnostic electron 
microscopy; negative staining; biosafety; virus 
 
1. Introduction 
Diagnostic electron microscopy of viruses is used as a “scouting” method in situations or diseases 
where speed of diagnostics is critical (e.g., in outbreaks of highly contagious diseases), or where the 
diagnosis remains unclear even after a first analysis by alternative screening techniques [1–4]. The key 
method in diagnostic electron microscopy is negative staining, and this mostly because the method is 
robust and well established [5–7], with extensive reference data available [8–10]. The main advantages 
of diagnostic negative staining electron microscopy are processing time (a single sample can be prepared 
and analyzed within an hour) and its generic approach, which means that electron microscopy (EM) is 
potentially able to detect all virus particles present in a sample, even viruses that are unknown or 
unsuspected [2,4]. Identification is based on morphological criteria allowing assignment of viruses to a 
morphological group, which is usually identical with the taxonomical category of a virus family [8]. 
Although this procedure does not allow identification of a specific virus species or strain, the diagnosis 
of the virus family (e.g., poxvirus versus herpesvirus) already helps to expedite a more specific diagnosis 
by providing an evidence–based hypothesis, which, for instance, facilitate the selection of reagents  
(such as those for PCR and immunological tests) for more specific identification down to the virus genus 
or species. 
Exposure of lab personnel and the public by accidentally released viruses during handling of  
virus–infected biological material must be avoided by efficient and feasible safety precautions.  
Since most electron microscopes are operated at biosafety level two and below, proper sample 
inactivation is necessary to guarantee biosafety [11–13]. For diagnostic purposes, the inactivation 
procedures must not only inactivate the viruses, but simultaneously preserve their morphology. 
Aldehyde fixation is well established in histology and EM [14]. In diagnostic negative staining EM, FA 
at a concentration of 2% to 4% is used because it stabilizes biological structures [14], and its virucidal 
efficiency is very well documented, e.g., in vaccination programs [15–19]. Glutaraldehyde (GA) is 
another very efficient inactivating agent if applied at a concentration of a few volume percent [20–22], 
but likely to cause aggregates and masks virus structures that are crucial for diagnosis [3,23].  
Other inactivating procedures, like the application of heat, alcohol, peroxide, or radiation may impair 
the structural features of the viruses [20] and are, therefore, not useful for diagnostic EM. Published data 
on the kinetics and concentration dependency of FA inactivation [24] suggest that the inactivation by 
classical FA–fixation may be effective. However, an experimental proof for the inactivation efficiency 
of the FA–fixation protocols used in diagnostic EM is still lacking. 
We therefore started to evaluate the inactivation efficiency of FA–fixation by using three different 
model viruses known for their environmental stability: a complex enveloped virus (Vaccinia virus),  
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a standard test virus in disinfection studies (Human adenovirus) and a more robust non–enveloped virus 
(Murine norovirus). Virus infectivity was determined before and after treatments by standardized 
methods (plaque or TCID50 assay). Structural integrity of inactivated viruses was checked by negative 
staining EM. As a main result of our study, we provide a rapid (1 h) inactivation protocol using 2% 
buffered FA, which completely inactivates concentrated virus suspensions. 
2. Experimental Section 
2.1. Virus Stocks and Cell Culture Systems 
Three different viruses were used for testing the inactivation efficiency. One complex, enveloped 
virus, Vaccinia virus (New York City Department of Health Laboratories; ATTC VR–1536), and two 
non–enveloped viruses, Murine norovirus (S99; Berlin/2006/DE) and Human adenovirus type 5 
(Adenoid 75 strain; ATCC VR–5). Three different poxvirus strains were used as additional positive 
control in each plaque assay: Cowpox virus (EP–GuWi; CPXV EleGri07/1 [25]), Cowpox virus 
(Brighton; ATCC VR–302) or Vaccinia virus (Lister Elstree; Bavarian-Nordic). Poxviruses were 
propagated in Hep2 cells (HeLa derivative; ECACC, No. 86030501), and plaque assays were  
performed using Vero C1008 cells (ECACC, No. 85020206). Murine norovirus was proliferated in 
RAW 264.7 cells (ATCC TIB–71) and Human adenovirus in A549 cells (ATCC CCL–185).  
Tissue culture infective dose 50 (TCID50) assays were conducted using the same cells, respectively. 
2.2. Virus Propagation and Harvesting 
2.2.1. Vaccinia Virus 
Hep2 cells infected with Vaccinia virus (MOI 0.5) were cultivated in Dulbecco’s Modified Eagle 
Medium (D–MEM), including 1% L-glutamine, (Gibco/Invitrogen) and 5% fetal bovine serum (PAA) 
for four days at 37 °C and 5% CO2. Cells with media of several culture flasks (175 cm2) were 
frozen/thawed thrice, scraped and pooled. Cell debris was sedimented by low speed centrifugation at 
724 g for 10 min, and the supernatant was ultracentrifuged at 20,000 rpm for 1.5 h (pre-cooled SW  
32 Ti rotor, Beckman Coulter) at 4 °C. The pellets were resuspended in D–MEM and stored at −80 °C 
until use as the stock solution for inactivation experiments. Virus titers were determined by plaque assay 
and ranged between 1.2 × 108 and 1.3 × 109 plaque forming units (PFU) per milliliter. 
2.2.2. Human Adenovirus 
A549 cells were infected with Human adenovirus type 5 and maintained in D–MEM including 1% 
L-glutamine, 1% non–essential amino acid cell culture supplement (100 × concentrate; PAA), 0.11% 
NaHCO3 and 2% fetal calf serum for 3–5 days at 37 °C and 5% CO2. Cells were scraped and centrifuged 
at 4696 g for 15 min. The pellets were frozen/thawed thrice and centrifuged again at 4696 g for 15 min. 
Supernatant was frozen at −80 °C and stored until usage as the stock solution for inactivation 
experiments. The virus titer was determined by tissue culture infective dose 50 (TCID50) assay and 
ranged between 1 × 109 and 1 × 1010 TCID50/mL. 
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2.2.3. Murine Norovirus 
Murine norovirus was propagated in Raw 264.7 cells, which were cultivated in Minimum Essential 
Medium (MEM) with Hank’s balanced salts (Invitrogen, 11012-044) and HEPES buffer, including 1% 
L-glutamine (200 mM; PAA), 1% sodium pyruvate (100 mM; PAA), 1% non–essential amino acid cell 
culture supplement (100×; PAA), 0.15% NaHCO3 and 3% fetal calf serum (Premium South Africa low 
endotoxin; PAN Biotech) for 3–5 days at 37 °C and 5% CO2. Cells were scraped and centrifuged at  
4696 g for 15 min. The pellets were frozen/thawed thrice and centrifuged again at 4696 g for 15 min. 
Supernatant was stored at −80 °C until usage as the stock solution for inactivation experiments. The 
virus titer of the virus preparations ranged between 1 × 107 and 1 × 108 TCID50/mL. 
2.3. Inactivation of Virus Suspensions 
Formaldehyde inactivation solution was prepared from a frozen stock solution of 20% 
paraformaldehyde (PFA; Roth, No. 0335.3) in 0.5 M HEPES buffer (pH 7.2), which was heated to  
60–70 °C for 20 min to shift the equilibrium towards non-polymerized FA. In the case of Vaccinia virus, 
a defined volume of the FA stock solution was added to samples (i.e., 1.8 mL for tests shown in Table 1 
or 0.9 mL in Table 4) of the virus stock solution and thereby diluted to the desired end concentration 
(i.e., 2% or 4% FA in 0.05 M HEPES buffer). Immediately after the end of incubation time (for 
inactivation conditions, refer to Tables 1–4) the test suspension was sedimented by ultracentrifugation 
at 65,000 rpm for 45 min at 4 °C (pre–cooled TLA–120.2 rotor, Beckman Coulter), collected in fresh 
D–MEM and frozen at −80 °C to quickly slow down chemical reactions and to prevent molecular 
mobility, which avoids reaction of free FA molecules with viruses. To estimate possible loss of infectious 
virions caused by ultracentrifugation, samples (2 and 1 mL) from one virus stock solution were 
ultracentrifuged, recovered in medium and analyzed by plaque assay. Infectivity of the two centrifuged 
samples was the same as infectivity of the virus stock solution (i.e., 2 × 108 PFU/mL). In the case of 
Human adenovirus and Murine norovirus, the PFA stock solution was diluted in HEPES buffer to a 
concentration of 2.2%, and nine units of the diluted PFA were mixed with one unit of the virus stock 
solution according to the DVV/RKI Guideline [26]. 
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Table 1. Efficiency of Vaccinia virus inactivation by 2% formaldehyde (if not stated 











4 2 1.2 × 108 1.3 × 103 4.9 
4 2 1.2 × 108 1.8 × 103 4.7 
4 48 1.2 × 108 2.6 × 103 4.5 
4 48 1.2 × 108 2.1 × 103 4.6 
4 168 1.2 × 108 1.4 × 103 4.9 
4 168 1.2 × 108 9.8 × 102 5.2 
25 2 1.6 × 108 no plaques complete 
25 2 1.6 × 108 no plaques complete 
25 (*) 3 1.3 × 109 1.1 × 101 8.2 
25 (*) 3 1.3 × 109 no plaques complete 
25 4 1.4 × 108 2.5 × 102 (***) 5.6 
25 4 1.4 × 108 no plaques complete 
25 4 1.4 × 108 no plaques complete 
25 4 1.4 × 108 no plaques complete 
25 4 1.6 × 108 no plaques complete 
25 4 1.6 × 108 no plaques complete 
25 6 1.4 × 108 2.5 × 102 (***) 5.6 
25 6 1.4 × 108 no plaques complete 
25 6 1.4 × 108 no plaques complete 
25 6 1.4 × 108 no plaques complete 
25 6 1.3 × 109 no plaques complete 
25 6 1.3 × 109 no plaques complete 
25 24 1.3 × 109 no plaques complete 
25 24 1.3 × 109 no plaques complete 
25/37 0.5/0.5 1.6 × 108 no plaques complete 
25/37 0.5/0.5 1.6 × 108 no plaques complete 
25/60 1/2 1.3 × 109 no plaques complete 
25/60 1/2 1.3 × 109 no plaques complete 
37 0.5 1.4 × 108 no plaques complete 
37 0.5 1.4 × 108 no plaques complete 
37 1 1.6 × 108 no plaques complete 
37 1 1.6 × 108 no plaques complete 
37 (**) 0.5 1.4 × 108 1.5 × 103 (***) 4.9 
37 (**) 0.5 1.4 × 108 no plaques complete 
37 (**) 0.5 1.4 × 108 no plaques complete 
37 (**) 0.5 1.4 × 108 no plaques complete 
(*) 4% FA; (**) 2% FA + 0.05% GA; (***) Note that residual infectivity was only detected at higher dilutions 
of the tests suspension in the plaque assay. 
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Table 2. Efficiency of Human adenovirus inactivation by formaldehyde at different 
temperatures. Virus titer was determined by TCID50 assay. 
Treatment Temperature (°C) Incubation Time (h) Virus Titer (log10 TCID50/mL) 
- 4 1 8.9 
2% FA 4 1 no CPE 
2% FA 4 1 no CPE 
- 25 1 8.5 
2% FA 25 1 no CPE 
2% FA 25 1 no CPE 
- 25/37 0.5/0.5 8.9 
2% FA 25/37 0.5/0.5 no CPE 
2% FA 25/37 0.5/0.5 no CPE 
CPE = cytopathic effect; Neutralization and toxicity tests performed as expected. 
Table 3. Efficiency of Murine norovirus inactivation by formaldehyde at different 
temperatures. Virus titer was determined by TCID50 assay. 
Treatment Temperature (°C) Incubation Time (h) Virus Titer (log10 TCID50/mL) 
- 4 1 7.2 
2% FA 4 1 4.4 
2% FA 4 1 4 
- 25 1 7.6 
2% FA 25 1 no CPE 
2% FA 25 1 no CPE 
- 25/37 0.5/0.5 7.4 
2% FA 25/37 0.5/0.5 no CPE 
2% FA 25/37 0.5/0.5 no CPE 
CPE = cytopathic effect; Neutralization and toxicity tests performed as expected. 
Table 4. Reproducibility of formaldehyde (2%) inactivation of Vaccinia virus. Virus titer 




Number of Tests Showing 
Plaques after Treatment (n = 10) 
4 1 1 
25° 24 0 
25/37° 0.5/0.5 0 
All controls showed expected values. 
2.4. Determination of Virus Infectivity 
2.4.1. Plaque Assays of Vaccinia Virus Infected Vero Cells 
Plaque assays were performed according to [27]. Prior to inoculation all samples were ultrasonicated 
(Branson Sonifier 450) until they were homogenized, i.e., no visible aggregates could be detected in the 
suspensions. For every FA-treated test suspension a 24–well plate (Nunc, Thermo Scientific) was 
prepared with 200 µL per well of a Vero cell suspension (1.2–1.5 × 106 cells/mL) supplemented with 
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5% streptomycin-penicillin (100× concentrate; PAA) followed by 200 µL of the virus suspension at 
three dilutions (1:10, 1:20, 1:200). The dilutions were generated in duplicates and distributed in four 
different wells (Figure S1 B–F). In our initial experiments we used a dilution of 1:2 but observed a 
cytotoxic effect most probably caused by residual FA molecules and therefore used dilutions equal to or 
above 1:10 in further experiments. Treated cells were incubated for four hours at 37 °C and 5% CO2 and 
then covered with 400 µL of 1.6% carboxymethyl cellulose solution in medium (BDH, No. 27649). 
After four days of incubation, cells were fixed with 3.7% formalin (Roth, P733.2) for 30 min, stained 
with amido black 10B (naphthalene black; Sigma, N3393-100G), washed with water, and plaques were 
counted manually. Untreated virus suspensions (virus stock solution of the test suspensions and control 
virus suspensions of established infectivity; see Section 2.1. for a detailed description of the viruses) 
were tested in the same manner in a 24–well plate by tenfold serial dilution 1:103 to 1:108 (Figure S1 A). 
Virus titers were calculated as plaque forming units per volume (PFU/mL), whereas either 1:10 or 1:20 
and 1:200 dilutions were considered in case of the inactivated test suspensions. The titer reduction (in 
log10 scale) was calculated relative to the virus titer estimated for the untreated virus suspension [28]. 
To increase statistical validity, selected inactivation tests were reproduced in ten separate assays each. 
In addition, a slightly modified plaque assay with an increased number of independent dilutions (four 
instead of two) of the test suspensions was applied (Table 4). In those assays virus was diluted 1:10 and 
1:100 for test suspensions inactivated at 4 °C. For samples inactivated at 25 or 37 °C the 1:100 dilution 
was not done, because negative results were expected. 
2.4.2. Determination of Tissue Culture Infective Dose 50 (TCID50) for Murine Norovirus and  
Human Adenovirus 
Tissue culture infective dose 50 (TCID50) was performed according to [26,29]. Cells were seeded in 
96–well plates (12 rows × 8 columns; TPP Lot 92096) and cultivated for one day at 37 °C and 5% CO2. 
Rows 9 to 11 were left blank to avoid contamination of the negative control (100 µL of virus-free 
medium), which was placed in row 12. The test suspension was sequentially diluted tenfold (from 1:10 
to 1:108) in medium (900 µL + 100 µL test suspension), supplemented with 0.5% (w/v) L-histidine to 
neutralize free aldehyde and 2% (Human adenovirus) or 3% (Murine norovirus) fetal calf serum. All 
dilutions were tested eightfold in a single 96–well plate. Untreated virus suspensions were tested in the 
same manner. Cytopathic effect (CPE) was evaluated after seven days for Human adenovirus and after 
five days in case of Murine norovirus using an inverted microscope. The virus titer was determined using 
the method of Spearman [30] and Kaerber [31] and expressed as tissue culture infective dose 50 per mL 
(TCID50/mL), which is the concentration that kills 50% of the cells. For the validation of the 
neutralization efficiency 8.9 mL L-histidine (0.5% w/v) + 1 mL of 2% PFA were incubated for 5 min at 
20 °C. Then 100 µL of a 1:100 dilution of unfixed virus suspension were added and incubated for  
30 min. Toxicity of the neutralizer was proven as follows: 9.9 mL L-histidine (0.5% w/v) + 100 µL of a 
1:100 dilution of unfixed virus suspension were incubated for 30 min. 10–fold dilutions of these 
validation tests and the untreated virus suspension were titrated on the related cells, respectively, to prove 
the correctness of test performance. 
  
Viruses 2015, 7 673 
 
 
2.5. Negative Staining Transmission Electron Microscopy 
Negative staining transmission electron microscopy of the virus stock solutions and test suspensions 
was performed according to [5]. A drop (10 µL) of the test suspension was placed directly onto a  
glow-discharged EM sample support (400 mesh copper grid, covered with a carbon reinforced plastic 
film). After adsorption for 10 min at room temperature, the grids were washed three times in double 
distilled water and negatively stained with 2% uranyl acetate, pH 4.5 (1% in case of Vaccinia virus).  
The grids were examined using a JEM–2100 transmission electron microscope (JEOL Corp.) operated 
at 200 KV. Micrographs were recorded with a Veleta CCD camera (Olympus Soft Imaging Solutions) 
at a resolution of 2048 × 2048 pixels. 
3. Results 
In electron microscopy, fixation is frequently performed at room temperature or even at 4 °C [32]. 
However, only few data are available on the fixation efficiency at different temperatures, which do not 
allow general conclusions ([33], page 57). To get an idea about the temperature/time dependence of the 
inactivation efficiency of the preferred formaldehyde (FA) fixation used in negative staining EM, we 
treated Vaccinia virus, Murine norovirus and Human adenovirus suspensions with 2% buffered FA at  
4 and 25 °C for different periods. The experiments demonstrated that short incubation times (one or two 
hours, respectively) at 4 °C are not sufficient to completely suppress infectivity of high concentrations  
(above 107 PFU/mL) of Murine norovirus and Vaccinia virus (Tables 1 and 3), while Human adenovirus 
is inactivated after a FA treatment at 4 °C for one hour (Table 2). At 25 °C some of the Vaccinia virus 
test suspensions showed residual infectivity, even if longer incubation times (up to six hours) were 
applied. Complete inactivation of Vaccinia virus infectivity was achieved by an incubation for 24 h at 
25 °C (Table 1). Infectivity of Human adenovirus and Murine norovirus was not observed after FA 
treatment of suspensions for at least one hour at 25 °C (Tables 2 and 3). 
Diagnostic electron microscopy of viruses is mainly used in emergency situations and therefore needs 
to be performed as quickly as possible. To find efficient and short inactivation conditions for inactivation 
by FA, we tested a higher concentration of FA, a combination with low concentration of glutaraldehyde 
(0.05%) and/or temperatures above 25 °C with the most resistant virus of our test viruses, i.e., Vaccinia 
virus. Our preliminary experiments suggested that temperature would be the most efficient parameter to 
accelerate a complete inactivation of highly concentrated Vaccinia virus. Incubations using 2% buffered 
FA at 37 or 60 °C for at least 30 min were sufficient to inactivate virus infectivity in a number of 
experiments (Table 1). Other strategies to increase the speed of inactivation failed. In the experiment, in 
which 0.05% GA was added to the 2% buffered FA, the virus suspension was not completely inactivated 
within 30 min at 37 °C, suggesting interference of the FA inactivation by GA or failure of the FA 
inactivation within the 30 min incubation time. Application of higher FA concentration, i.e., 4% FA, for 
3 h at 25 °C was also not sufficient to block infectivity of the test suspension (Table 1). The efficiency 
of FA inactivation at higher temperature was also tested for Murine norovirus and Human adenovirus. 
No cytopathic effect in TCID50 assays could be detected after treatment of virus suspensions with 2% 
buffered FA for 30 min at 25 °C followed by 30 min at 37 °C (Tables 2 and 3). 
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In order to ascertain the relevance of our findings, we repeated selected inactivation schemes in ten 
independent inactivation experiments, each using Vaccinia virus as a model and a slightly modified 
plaque assay (see Section 2.4.1. for details). Besides inactivation at 4 °C for one hour, tests at 25 °C for 
24 h and a temperature–shift protocol (0.5 h for 25 and 0.5 h at 37 °C) were performed. Virus infectivity 
was found in one of ten samples inactivated at 4 °C. This residual activity was shown consistently in all 
of the four independent dilutions of the sample which were deployed for plaque testing. All of the other 
test suspensions did not show any residual infectivity (Table 4). Controls, especially controls using 
different untreated poxvirus suspensions (see Section 2.4.1. for details), showed the expected results, 
indicating no significant bias in the detection of virus infectivity. 
The morphological integrity of virus particles was checked by negative staining electron microscopy. 
Virus morphology was not affected by the inactivation using the temperature–shift protocol (25/37 °C, 
0.5/0.5 h) (Figure 1). Samples inactivated by other protocols were only occasionally evaluated by 
negative staining EM but never revealed any significant structural impairment. 
 
Figure 1. Negative staining EM of untreated and treated virions. (A–C): Untreated stock 
suspensions; (D–F): Test suspensions treated with 2% FA at 25/37 °C for 30 min at each 
temperature (temperature-shift protocol); (A) and (D): Vaccinia virus VR–1536, bar = 200 nm; 
(B) and (E): Human adenovirus type 5, adenoid 75 strain, bar = 100 nm; (C) and (F): Murine 
norovirus S99, bar = 100 nm. 
  




Our results show that the inactivation of virus suspensions by FA depends on temperature, incubation 
time and the type of virus. This result and the influence of other factors, like pH and FA concentration 
on inactivation efficiency, have been documented by other studies before (reviewed in [15,24,34]) and 
therefore was not surprising. However, we showed that a buffered FA solution of 2%, which is 
commonly applied in diagnostic electron microscopy of viruses, needs at least room temperature  
(i.e., 25 °C) and rather long incubation time (more than six hours) to completely inactivate complex 
viruses such as the Vaccinia virus. Although temperature dependency of FA inactivation is known, it 
came as a surprise that even an exposure of Vaccinia virus to 2% FA for several days at 4 °C did not 
fully inactivate the virus. The non–enveloped viruses tested were much more susceptible to FA treatment 
at low temperature than the enveloped Vaccinia virus, but showed also differences in their reactivity, 
indicating slow reactivity of the FA at 4 °C. In summary, we concluded that inactivation of viruses at  
4 °C should be avoided. Inactivation at 25 °C was much more efficient but still needed several hours for 
a complete inactivation of concentrated suspensions of the complex Vaccinia virus. A significant 
reduction in incubation time to reach complete inactivation was found with a further increase of 
temperature to 37 °C after a pre-treatment at 25 °C (temperature–shift protocol). With a total inactivation 
time of 60 min, the temperature-shift protocol becomes useful for emergency diagnostics. It seems likely 
that further modifications of the protocol, like increasing temperature to higher levels than 37 °C, could 
shorten the complete inactivation even further. Increasing the FA concentration (e.g., to 10%) could also 
accelerate inactivation [35]. However, the rapidity of inactivation must be carefully balanced against the 
residual risk of incomplete inactivation, ultrastructural preservation and visibility, which is necessary 
for the generic detection capabilities of diagnostic EM. 
It was not our goal to study the virucidal properties of FA in detail, but rather to develop an  
inactivation protocol that is useful in practice. The temperature-shift protocol provides appropriate speed 
and safety especially for application in emergencies. Inactivation at 25 °C may also be used for 
diagnostic samples if incubation time can be extended to 24 h. However, the following concerns remain 
and need further investigation: 
(1) The inactivation of viruses by FA has been evaluated by using three different test viruses, and 
results showed that the inactivation efficiency is highly dependent on the virus type, as expected 
(e.g., [36]). While our results allow already generalized conclusions, tests using other viruses, 
even more resistant viruses than poxviruses (e.g., small non-enveloped viruses, like parvo- and 
circoviruses [34,37]), must be performed to prove the inactivation efficiency of the so far 
successful protocols. 
(2) The inactivation tests have been conducted using non–purified cell culture supernatants. 
Although these samples contain biological macromolecules besides virus particles released  
by the cells in culture, concentration of such material is rather low in comparison to some 
diagnostic samples, e.g., serum or stool. Therefore, additional experiments, using defined loads 
of protein or other biological material (e.g., urine, cell or tissue homogenates), must be performed 
to determine the possible interference of the inactivation by high concentrations of other 
biological material. 
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(3) Concentration of viruses may also be a critical factor for inactivation efficiency. To produce  
high concentrations and sufficient amount of active test viruses is difficult and laborious. In our 
tests, we used concentrations up to 109 PFU/mL of the highly stable poxviruses. Although the 
situation of diagnosing a sample with higher virus load seems rather unlikely, it should be 
investigated whether the proposed inactivation protocols are efficient at even higher 
concentrations or not. 
(4) Our results showed a slight variability in the inactivation efficiency, even under ideal 
experimental conditions. The poxvirus suspension used for the reproduction experiments  
(Table 4) was more sensitive for FA inactivation at low temperature than the poxvirus suspension 
used in the preliminary experiments (Table 1). Variability may be due to differences in the 
sensitivity of varying virus batches, which has been suggested before [24]. Another possibility 
could be a difference in the homogenization efficiency of the different virus batches, which could 
result in a variable number and size of virus aggregates. Aggregation is a well-known factor, 
which affects inactivation efficiency of many disinfectants [38] and could be the reason for the 
observed residual infectivity in few of the treated Vaccinia virus suspensions which became 
apparent only at higher dilutions in the plaque test. Higher dilution could have promoted 
disintegration of aggregates and release of infectious particles. Further experiments must 
consider these variables and should provide an estimate regarding their effects. 
(5) For an application of the suggested inactivation protocols in emergency diagnostics, the 
inactivation efficiency of the protocols must be tested also for bacteria, since a pre-screening of 
the samples for bacteria is not possible in any case. From the published data on FA inactivation, 
at least a significant reduction of vegetative bacteria can be expected [39,40]. Bacterial spores 
are much more resistant to FA inactivation than their vegetative forms (for a review see [41]), 
but FA is able to penetrate even the spore core, which houses the DNA [42]. Increased incubation 
temperature may help to improve inactivation efficiency. Addition of glutaraldehyde may also 
be considered, because it is not only efficient against spores [43] but also against viruses and 
vegetative bacteria [39]. Low concentration of GA will minimize GA interference with the 
detection of viruses by negative staining EM [3,20]. However, it cannot be excluded that addition 
of GA may interfere with the FA inactivation. Further experiments are necessary to clearly prove 
efficiency of the proposed protocols for bacteria. 
In summary, the application of the inactivation protocols as suggested in this paper bears a residual 
risk of incomplete inactivation, which cannot be quantified so far. Since the negative staining procedure 
and electron microscopy itself seem not to inactivate virus samples [3], a residual activity of the 
inactivated samples prepared for diagnostic electron microscopy must be considered. However,  
a considerable decrease of the infective dose will be achieved by applying the temperature-shift protocol, 
which reduces the risk of accidental spread of infectious material significantly. As a consequence, even 
inactivated samples must be treated by proper means of hygiene, e.g., preparation in a biosafety cabinet, 
safe transport and decontamination of contaminated items. Future experiments should expand testing of 
the suggested protocols to high amounts of small non-enveloped viruses, which are considered as the 
most stable virions in disinfection tests [34,37] and other pathogens under various realistic conditions, 
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to further improve the biosafety of diagnostic EM. Thus far, the temperature-shift protocol is the most 
efficient and validated inactivation procedure that is available for rapid diagnostic EM of viruses. 
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